Clinical Trials Logo

Delayed Graft Function clinical trials

View clinical trials related to Delayed Graft Function.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02658162 Withdrawn - Clinical trials for Delayed Function of Renal Transplant

A Study on SANGUINATEā„¢ for the Reduction of Delayed Graft Function in Kidney Transplant Patients

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.

NCT ID: NCT02312115 Withdrawn - Clinical trials for Delayed Graft Function

Delayed Renal Allograft Function and Furosemide Treatment

DRAFFT
Start date: September 2016
Phase: Phase 2
Study type: Interventional

This study will be a randomized prospective double-blind placebo-controlled clinical pilot trial. This will be a single center project that will take place at Loma Linda University Medical Center. All adult kidney recipients will be informed of the study prior to operation. The Nephrology fellows or attending physicians will attempt to obtain informed consent from all eligible patients, pre-transplant. Those patients who consent will be screened post operation for enrollment. Patients who do not meet all eligibility criteria and/or who meet some exclusion criteria will be deemed ineligible for the trial, and will be excluded. The Nephrology and Transplant teams will be blinded of patient assignment and only the pharmacy will know the patient's assignment.

NCT ID: NCT02130817 Withdrawn - Clinical trials for End Stage Renal Disease

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

BelatPilot
Start date: September 24, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a standard of care regimen of immunosuppressive medications and plasma exchange (plasmapheresis and immunoglobulin treatment) for kidney transplant patients who are moderately sensitized against their deceased donor and at-risk for delayed graft function. The hypothesis is that moderately sensitized patients who receive Belatacept treatment with the standard of care regimen will lead to lower acute rejection rates than historical controls based on assessment of standard of care biopsies and standard Banff criteria.